Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
Journal
Respiratory medicine
Journal Volume
178
Pages
106220
Date Issued
2021-03
Author(s)
Ghofrani, Hossein-Ardeschir
Gomez Sanchez, Miguel-Angel
Humbert, Marc
Pittrow, David
Simonneau, Gérald
Gall, Henning
Grünig, Ekkehard
Klose, Hans
Halank, Michael
et al.
Abstract
The soluble guanylate cyclase stimulator riociguat is approved for the treatment of adult patients with pulmonary arterial hypertension (PAH) and inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following Phase 3 randomized trials. The EXPosurE Registry RiociguaT in patients with pulmonary hypertension (EXPERT) study was designed to monitor the long-term safety of riociguat in clinical practice.
Subjects
Chronic thromboembolic pulmonary hypertension; Clinical practice; Real-world; Registry; Riociguat; Safety
SDGs
Other Subjects
ambrisentan; bosentan; guanylate cyclase; iloprost; macitentan; prostacyclin; prostanoid; riociguat; treprostinil; pyrazole derivative; pyrimidine derivative; riociguat; adverse event; aged; Article; chronic thromboembolic pulmonary hypertension; clinical practice; clinical trial; cohort analysis; combination drug therapy; disease registry; dizziness; drug safety; dyspnea; faintness; female; heart right ventricle failure; hemoptysis; human; hypotension; lung hemorrhage; major clinical study; male; Medical Dictionary for Regulatory Activities; monotherapy; multicenter study; peripheral edema; phase 3 clinical trial; pneumonia; priority journal; prospective study; pulmonary hypertension; randomized controlled trial; chronic disease; complication; data analysis; lung embolism; middle aged; multicenter study (topic); pulmonary hypertension; randomized controlled trial (topic); recurrent disease; register; safety; time factor; treatment outcome; Aged; Chronic Disease; Data Analysis; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Pulmonary Embolism; Pyrazoles; Pyrimidines; Randomized Controlled Trials as Topic; Recurrence; Registries; Safety; Time Factors; Treatment Outcome
Type
journal article